Research programme: anti-cancer therapeutics - AriBio

Drug Profile

Research programme: anti-cancer therapeutics - AriBio

Alternative Names: AR 1002; AR 1011

Latest Information Update: 13 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AriBio
  • Class Antineoplastics
  • Mechanism of Action RNA synthesis inhibitors; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Colorectal cancer
  • Research Cancer

Most Recent Events

  • 01 Jun 2016 Early research in Cancer in South Korea (unspecified route)
  • 01 Jun 2016 Preclinical trials in Colorectal cancer in South Korea (unspecified route)
  • 01 Jun 2016 AriBio plans a phase I trial for Colorectal cancer in USA and South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top